SCHEMBL7939210

SCHEMBL7939210

[CH]=Cc1ccc2ccc(Cl)cc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.46
HTR3E A5X5Y0 1/20 0.40
HTR3B O95264 1/20 0.40
HTR3A P46098 1/20 0.40
HTR3D Q70Z44 1/20 0.40
HTR3C Q8WXA8 1/20 0.40
CYSLTR2 Q9NS75 5/20 0.39
CYSLTR1 Q9Y271 5/20 0.39
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HRH3 Q9Y5N1 1/20 0.37
F7 P08709 1/20 0.36
F3 P13726 1/20 0.36
DYRK1A Q13627 1/20 0.36
PIK3CG P48736 1/20 0.36
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36
MAPK1 P28482 2/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3748357 0.80 CCR1 (0.48) NR4A2HTR3EHTR3BHTR3AHTR3D
SCHEMBL627005 0.80 S1PR4 (0.46) NR4A2HTR3EHTR3BHTR3AHTR3D
SCHEMBL6750524 0.73 KDM4E (0.67) CYSLTR2CYSLTR1KDM4EMEN1KMT2A
SCHEMBL13513030 0.73 CYSLTR1 (0.59) CYSLTR2CYSLTR1KDM4EMEN1KMT2A
SCHEMBL4476236 0.72 NPC1 (0.57) CYSLTR2CYSLTR1KDM4EMEN1KMT2A
SCHEMBL5833376 0.72 NR4A2 (0.50) NR4A2HTR3EHTR3BHTR3AHTR3D
SCHEMBL30506415 0.72 NR4A2 (0.54) NR4A2HTR3EHTR3BHTR3AHTR3D
SCHEMBL2133059 0.72 NR4A2 (0.54) NR4A2HTR3EHTR3BHTR3AHTR3D
SCHEMBL10421430 0.71 KDM4E (0.65) CYSLTR2CYSLTR1KDM4EMEN1KMT2A
SCHEMBL6969863 0.71 CYSLTR2 (0.48) CYSLTR2CYSLTR1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102690229-A Brand new synthesis of Montelukast Sodium and its preparation intermediates SHANGHAI XIANGHUI MEDICAL TECHNOLOGY CO LTD 2012-09-26 CN claimed
CN-101808997-A Process and intermediates for the production of tertiary alcohols as intermediates in the synthesis of montelukast LONZA AG 2010-08-18 CN claimed
CN-101356158-B intermediates for the preparation of montelukast and related compounds SYNTHON B.V. (NL) 2011-12-14 CN disclosed
CN-101356157-B Process for making montelukast and intermediates therefor SYNTHON BV 2011-07-06 CN disclosed
CN-101889081-A Ketoreductase polypeptides and uses thereof CODEXIS INC 2010-11-17 CN disclosed
CN-101365683-A Process for making montelukast and intermediates therefor SYNTHON BV (NL) 2009-02-11 CN disclosed
CN-101356157-A Process for making montelukast and intermediates therefor SYNTHON BV (NL) 2009-01-28 CN disclosed
CN-101356158-A Novel intermediates for the preparation of montelukast and related compounds SYNTHON BV (NL) 2009-01-28 CN disclosed
EP-1123091-A1 COMBINATION PRODUCT COMPRISING AN E-TYPE PROSTAGLANDIN LIGAND AND A COX-2 SELECTIVE INHIBITOR AND METHODS OF USE Merck Frosst Canada & Co. (CA) 2001-08-16 EP disclosed
WO-2000024393-A1 COMBINATION PRODUCT COMPRISING AN E-TYPE PROSTAGLANDIN LIGAND AND A COX-2 SELECTIVE INHIBITOR AND METHODS OF USE MERCK FROSST CANADA & CO. (CA) 2000-05-04 WO disclosed
CN-1040108-C Pharmaceutical compounds LILLY INDUSTRIES LTD (GB) 1998-10-07 CN disclosed